nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP3A4—bone cancer	0.772	1	CbGaD
Atomoxetine—HTR1B—dura mater—bone cancer	0.0251	0.225	CbGeAlD
Atomoxetine—HTR1D—dura mater—bone cancer	0.0243	0.218	CbGeAlD
Atomoxetine—HTR1B—trigeminal nerve—bone cancer	0.0108	0.0968	CbGeAlD
Atomoxetine—HTR1D—trigeminal nerve—bone cancer	0.0104	0.0937	CbGeAlD
Atomoxetine—HTR1B—cranial nerve—bone cancer	0.00768	0.069	CbGeAlD
Atomoxetine—HTR1D—cranial nerve—bone cancer	0.00743	0.0668	CbGeAlD
Atomoxetine—HTR2A—trigeminal nerve—bone cancer	0.00518	0.0466	CbGeAlD
Atomoxetine—HTR2A—cranial nerve—bone cancer	0.00369	0.0332	CbGeAlD
Atomoxetine—HTR2A—vertebral column—bone cancer	0.00362	0.0325	CbGeAlD
Atomoxetine—HTR2A—hindlimb—bone cancer	0.00311	0.028	CbGeAlD
Atomoxetine—HTR2A—appendage—bone cancer	0.00267	0.024	CbGeAlD
Atomoxetine—HTR1D—connective tissue—bone cancer	0.00153	0.0138	CbGeAlD
Atomoxetine—HTR1B—spinal cord—bone cancer	0.00105	0.00944	CbGeAlD
Atomoxetine—SLC6A3—spinal cord—bone cancer	0.00104	0.00936	CbGeAlD
Atomoxetine—HTR2C—spinal cord—bone cancer	0.00101	0.00905	CbGeAlD
Atomoxetine—SLC6A4—spinal cord—bone cancer	0.000954	0.00858	CbGeAlD
Atomoxetine—Reboxetine—CYP3A4—bone cancer	0.000873	0.123	CrCbGaD
Atomoxetine—HTR2A—connective tissue—bone cancer	0.000762	0.00685	CbGeAlD
Atomoxetine—Fenoprofen—PTGS2—bone cancer	0.000639	0.09	CrCbGaD
Atomoxetine—Tolterodine—CYP3A4—bone cancer	0.000574	0.0808	CrCbGaD
Atomoxetine—Phenprocoumon—CYP3A4—bone cancer	0.000563	0.0792	CrCbGaD
Atomoxetine—Fluoxetine—CYP3A4—bone cancer	0.000547	0.0771	CrCbGaD
Atomoxetine—Coma—Epirubicin—bone cancer	0.00054	0.00582	CcSEcCtD
Atomoxetine—Flushing—Cisplatin—bone cancer	0.000536	0.00578	CcSEcCtD
Atomoxetine—Cardiac disorder—Cisplatin—bone cancer	0.000536	0.00578	CcSEcCtD
Atomoxetine—HTR2A—tendon—bone cancer	0.000524	0.00471	CbGeAlD
Atomoxetine—Mediastinal disorder—Cisplatin—bone cancer	0.000521	0.00561	CcSEcCtD
Atomoxetine—Hepatic failure—Methotrexate—bone cancer	0.00051	0.0055	CcSEcCtD
Atomoxetine—HTR2A—spinal cord—bone cancer	0.000505	0.00454	CbGeAlD
Atomoxetine—Malnutrition—Cisplatin—bone cancer	0.000503	0.00542	CcSEcCtD
Atomoxetine—Coma—Doxorubicin—bone cancer	0.0005	0.00539	CcSEcCtD
Atomoxetine—Warfarin—CYP3A4—bone cancer	0.000499	0.0703	CrCbGaD
Atomoxetine—Flatulence—Cisplatin—bone cancer	0.000496	0.00534	CcSEcCtD
Atomoxetine—Propafenone—CYP3A4—bone cancer	0.000488	0.0687	CrCbGaD
Atomoxetine—Muscle spasms—Cisplatin—bone cancer	0.000484	0.00521	CcSEcCtD
Atomoxetine—Hepatic failure—Epirubicin—bone cancer	0.000477	0.00514	CcSEcCtD
Atomoxetine—Vision blurred—Cisplatin—bone cancer	0.000474	0.00511	CcSEcCtD
Atomoxetine—Tremor—Cisplatin—bone cancer	0.000471	0.00508	CcSEcCtD
Atomoxetine—Lethargy—Methotrexate—bone cancer	0.000468	0.00504	CcSEcCtD
Atomoxetine—Hot flush—Epirubicin—bone cancer	0.000459	0.00494	CcSEcCtD
Atomoxetine—Menopausal symptoms—Epirubicin—bone cancer	0.000455	0.0049	CcSEcCtD
Atomoxetine—Hepatic failure—Doxorubicin—bone cancer	0.000442	0.00476	CcSEcCtD
Atomoxetine—Lethargy—Epirubicin—bone cancer	0.000438	0.00472	CcSEcCtD
Atomoxetine—Irritability—Methotrexate—bone cancer	0.000438	0.00472	CcSEcCtD
Atomoxetine—Convulsion—Cisplatin—bone cancer	0.000436	0.0047	CcSEcCtD
Atomoxetine—Mood swings—Methotrexate—bone cancer	0.000434	0.00468	CcSEcCtD
Atomoxetine—Myalgia—Cisplatin—bone cancer	0.000428	0.00462	CcSEcCtD
Atomoxetine—Anxiety—Cisplatin—bone cancer	0.000427	0.0046	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000425	0.00458	CcSEcCtD
Atomoxetine—Hot flush—Doxorubicin—bone cancer	0.000424	0.00457	CcSEcCtD
Atomoxetine—Affect lability—Epirubicin—bone cancer	0.000422	0.00455	CcSEcCtD
Atomoxetine—Menopausal symptoms—Doxorubicin—bone cancer	0.000421	0.00453	CcSEcCtD
Atomoxetine—Breast disorder—Methotrexate—bone cancer	0.000414	0.00446	CcSEcCtD
Atomoxetine—Modafinil—CYP3A4—bone cancer	0.000409	0.0576	CrCbGaD
Atomoxetine—Infection—Cisplatin—bone cancer	0.000408	0.0044	CcSEcCtD
Atomoxetine—Mood swings—Epirubicin—bone cancer	0.000406	0.00438	CcSEcCtD
Atomoxetine—Lethargy—Doxorubicin—bone cancer	0.000405	0.00437	CcSEcCtD
Atomoxetine—Nervous system disorder—Cisplatin—bone cancer	0.000403	0.00434	CcSEcCtD
Atomoxetine—Tachycardia—Cisplatin—bone cancer	0.000401	0.00432	CcSEcCtD
Atomoxetine—Skin disorder—Cisplatin—bone cancer	0.000399	0.0043	CcSEcCtD
Atomoxetine—Hyperhidrosis—Cisplatin—bone cancer	0.000397	0.00428	CcSEcCtD
Atomoxetine—Abdominal pain upper—Epirubicin—bone cancer	0.000392	0.00422	CcSEcCtD
Atomoxetine—Anorexia—Cisplatin—bone cancer	0.000391	0.00422	CcSEcCtD
Atomoxetine—Affect lability—Doxorubicin—bone cancer	0.000391	0.00421	CcSEcCtD
Atomoxetine—Breast disorder—Epirubicin—bone cancer	0.000388	0.00418	CcSEcCtD
Atomoxetine—Nasopharyngitis—Epirubicin—bone cancer	0.000384	0.00413	CcSEcCtD
Atomoxetine—Abdominal discomfort—Methotrexate—bone cancer	0.00038	0.00409	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS2—bone cancer	0.000377	0.0531	CrCbGaD
Atomoxetine—Mood swings—Doxorubicin—bone cancer	0.000376	0.00405	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000374	0.00403	CcSEcCtD
Atomoxetine—Influenza—Epirubicin—bone cancer	0.000371	0.004	CcSEcCtD
Atomoxetine—Dysuria—Methotrexate—bone cancer	0.000371	0.00399	CcSEcCtD
Atomoxetine—Paraesthesia—Cisplatin—bone cancer	0.000369	0.00397	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Methotrexate—bone cancer	0.000368	0.00397	CcSEcCtD
Atomoxetine—Erectile dysfunction—Methotrexate—bone cancer	0.000365	0.00393	CcSEcCtD
Atomoxetine—Abdominal pain upper—Doxorubicin—bone cancer	0.000363	0.00391	CcSEcCtD
Atomoxetine—Breast disorder—Doxorubicin—bone cancer	0.000359	0.00387	CcSEcCtD
Atomoxetine—Decreased appetite—Cisplatin—bone cancer	0.000357	0.00385	CcSEcCtD
Atomoxetine—Nasopharyngitis—Doxorubicin—bone cancer	0.000355	0.00383	CcSEcCtD
Atomoxetine—Benzphetamine—CYP3A4—bone cancer	0.000355	0.0499	CrCbGaD
Atomoxetine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000355	0.00382	CcSEcCtD
Atomoxetine—Infestation NOS—Methotrexate—bone cancer	0.000353	0.00381	CcSEcCtD
Atomoxetine—Infestation—Methotrexate—bone cancer	0.000353	0.00381	CcSEcCtD
Atomoxetine—Depression—Methotrexate—bone cancer	0.000352	0.0038	CcSEcCtD
Atomoxetine—Pain—Cisplatin—bone cancer	0.000351	0.00378	CcSEcCtD
Atomoxetine—Dysuria—Epirubicin—bone cancer	0.000347	0.00374	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Epirubicin—bone cancer	0.000345	0.00371	CcSEcCtD
Atomoxetine—Conjunctivitis—Methotrexate—bone cancer	0.000343	0.0037	CcSEcCtD
Atomoxetine—Influenza—Doxorubicin—bone cancer	0.000343	0.0037	CcSEcCtD
Atomoxetine—Pollakiuria—Epirubicin—bone cancer	0.000343	0.00369	CcSEcCtD
Atomoxetine—Phenoxybenzamine—CYP3A4—bone cancer	0.000339	0.0477	CrCbGaD
Atomoxetine—Feeling abnormal—Cisplatin—bone cancer	0.000338	0.00365	CcSEcCtD
Atomoxetine—Weight decreased—Epirubicin—bone cancer	0.000335	0.00362	CcSEcCtD
Atomoxetine—Propranolol—CYP3A4—bone cancer	0.000334	0.047	CrCbGaD
Atomoxetine—Infestation NOS—Epirubicin—bone cancer	0.000331	0.00356	CcSEcCtD
Atomoxetine—Infestation—Epirubicin—bone cancer	0.000331	0.00356	CcSEcCtD
Atomoxetine—Body temperature increased—Cisplatin—bone cancer	0.000325	0.0035	CcSEcCtD
Atomoxetine—Conjunctivitis—Epirubicin—bone cancer	0.000321	0.00346	CcSEcCtD
Atomoxetine—Dysuria—Doxorubicin—bone cancer	0.000321	0.00346	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000319	0.00344	CcSEcCtD
Atomoxetine—Pollakiuria—Doxorubicin—bone cancer	0.000317	0.00342	CcSEcCtD
Atomoxetine—Urinary tract disorder—Methotrexate—bone cancer	0.000313	0.00338	CcSEcCtD
Atomoxetine—Urethral disorder—Methotrexate—bone cancer	0.000311	0.00335	CcSEcCtD
Atomoxetine—Weight decreased—Doxorubicin—bone cancer	0.00031	0.00335	CcSEcCtD
Atomoxetine—Sinusitis—Epirubicin—bone cancer	0.00031	0.00334	CcSEcCtD
Atomoxetine—Nortriptyline—CYP3A4—bone cancer	0.000307	0.0433	CrCbGaD
Atomoxetine—Infestation NOS—Doxorubicin—bone cancer	0.000306	0.0033	CcSEcCtD
Atomoxetine—Infestation—Doxorubicin—bone cancer	0.000306	0.0033	CcSEcCtD
Atomoxetine—Conjunctivitis—Doxorubicin—bone cancer	0.000297	0.0032	CcSEcCtD
Atomoxetine—Hypoaesthesia—Epirubicin—bone cancer	0.000295	0.00318	CcSEcCtD
Atomoxetine—Asthenia—Cisplatin—bone cancer	0.000295	0.00317	CcSEcCtD
Atomoxetine—Cardiac disorder—Methotrexate—bone cancer	0.000294	0.00317	CcSEcCtD
Atomoxetine—Urinary tract disorder—Epirubicin—bone cancer	0.000293	0.00316	CcSEcCtD
Atomoxetine—Urethral disorder—Epirubicin—bone cancer	0.000291	0.00314	CcSEcCtD
Atomoxetine—Angiopathy—Methotrexate—bone cancer	0.000288	0.0031	CcSEcCtD
Atomoxetine—Sinusitis—Doxorubicin—bone cancer	0.000287	0.00309	CcSEcCtD
Atomoxetine—Mediastinal disorder—Methotrexate—bone cancer	0.000286	0.00308	CcSEcCtD
Atomoxetine—Chills—Methotrexate—bone cancer	0.000285	0.00307	CcSEcCtD
Atomoxetine—Diarrhoea—Cisplatin—bone cancer	0.000281	0.00303	CcSEcCtD
Atomoxetine—Mental disorder—Methotrexate—bone cancer	0.000278	0.00299	CcSEcCtD
Atomoxetine—Malnutrition—Methotrexate—bone cancer	0.000276	0.00298	CcSEcCtD
Atomoxetine—Cardiac disorder—Epirubicin—bone cancer	0.000275	0.00297	CcSEcCtD
Atomoxetine—Flushing—Epirubicin—bone cancer	0.000275	0.00297	CcSEcCtD
Atomoxetine—Methadone—CYP3A4—bone cancer	0.000274	0.0386	CrCbGaD
Atomoxetine—Hypoaesthesia—Doxorubicin—bone cancer	0.000273	0.00294	CcSEcCtD
Atomoxetine—Urinary tract disorder—Doxorubicin—bone cancer	0.000271	0.00292	CcSEcCtD
Atomoxetine—Dysgeusia—Methotrexate—bone cancer	0.00027	0.00291	CcSEcCtD
Atomoxetine—Angiopathy—Epirubicin—bone cancer	0.000269	0.0029	CcSEcCtD
Atomoxetine—Urethral disorder—Doxorubicin—bone cancer	0.000269	0.0029	CcSEcCtD
Atomoxetine—Orphenadrine—CYP3A4—bone cancer	0.000269	0.0378	CrCbGaD
Atomoxetine—Mediastinal disorder—Epirubicin—bone cancer	0.000267	0.00288	CcSEcCtD
Atomoxetine—Back pain—Methotrexate—bone cancer	0.000267	0.00288	CcSEcCtD
Atomoxetine—Chills—Epirubicin—bone cancer	0.000266	0.00287	CcSEcCtD
Atomoxetine—Vomiting—Cisplatin—bone cancer	0.000261	0.00281	CcSEcCtD
Atomoxetine—Vision blurred—Methotrexate—bone cancer	0.00026	0.0028	CcSEcCtD
Atomoxetine—Mental disorder—Epirubicin—bone cancer	0.00026	0.0028	CcSEcCtD
Atomoxetine—Rash—Cisplatin—bone cancer	0.000259	0.00279	CcSEcCtD
Atomoxetine—Dermatitis—Cisplatin—bone cancer	0.000259	0.00279	CcSEcCtD
Atomoxetine—Malnutrition—Epirubicin—bone cancer	0.000258	0.00278	CcSEcCtD
Atomoxetine—Flushing—Doxorubicin—bone cancer	0.000255	0.00275	CcSEcCtD
Atomoxetine—Cardiac disorder—Doxorubicin—bone cancer	0.000255	0.00275	CcSEcCtD
Atomoxetine—Flatulence—Epirubicin—bone cancer	0.000255	0.00274	CcSEcCtD
Atomoxetine—Tension—Epirubicin—bone cancer	0.000254	0.00273	CcSEcCtD
Atomoxetine—Dysgeusia—Epirubicin—bone cancer	0.000253	0.00273	CcSEcCtD
Atomoxetine—Desipramine—CYP3A4—bone cancer	0.000253	0.0356	CrCbGaD
Atomoxetine—Nervousness—Epirubicin—bone cancer	0.000251	0.0027	CcSEcCtD
Atomoxetine—Back pain—Epirubicin—bone cancer	0.00025	0.00269	CcSEcCtD
Atomoxetine—Angiopathy—Doxorubicin—bone cancer	0.000249	0.00269	CcSEcCtD
Atomoxetine—Muscle spasms—Epirubicin—bone cancer	0.000248	0.00268	CcSEcCtD
Atomoxetine—Vertigo—Methotrexate—bone cancer	0.000248	0.00267	CcSEcCtD
Atomoxetine—Mediastinal disorder—Doxorubicin—bone cancer	0.000248	0.00267	CcSEcCtD
Atomoxetine—Chills—Doxorubicin—bone cancer	0.000246	0.00266	CcSEcCtD
Atomoxetine—Nausea—Cisplatin—bone cancer	0.000244	0.00263	CcSEcCtD
Atomoxetine—Vision blurred—Epirubicin—bone cancer	0.000243	0.00262	CcSEcCtD
Atomoxetine—Cough—Methotrexate—bone cancer	0.000241	0.0026	CcSEcCtD
Atomoxetine—Mental disorder—Doxorubicin—bone cancer	0.000241	0.00259	CcSEcCtD
Atomoxetine—Convulsion—Methotrexate—bone cancer	0.000239	0.00258	CcSEcCtD
Atomoxetine—Malnutrition—Doxorubicin—bone cancer	0.000239	0.00258	CcSEcCtD
Atomoxetine—Agitation—Epirubicin—bone cancer	0.000237	0.00256	CcSEcCtD
Atomoxetine—Flatulence—Doxorubicin—bone cancer	0.000236	0.00254	CcSEcCtD
Atomoxetine—Arthralgia—Methotrexate—bone cancer	0.000235	0.00253	CcSEcCtD
Atomoxetine—Myalgia—Methotrexate—bone cancer	0.000235	0.00253	CcSEcCtD
Atomoxetine—Chest pain—Methotrexate—bone cancer	0.000235	0.00253	CcSEcCtD
Atomoxetine—Tension—Doxorubicin—bone cancer	0.000235	0.00253	CcSEcCtD
Atomoxetine—Dysgeusia—Doxorubicin—bone cancer	0.000234	0.00252	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000233	0.00252	CcSEcCtD
Atomoxetine—Nervousness—Doxorubicin—bone cancer	0.000232	0.0025	CcSEcCtD
Atomoxetine—Vertigo—Epirubicin—bone cancer	0.000232	0.0025	CcSEcCtD
Atomoxetine—Syncope—Epirubicin—bone cancer	0.000232	0.0025	CcSEcCtD
Atomoxetine—Back pain—Doxorubicin—bone cancer	0.000231	0.00249	CcSEcCtD
Atomoxetine—Muscle spasms—Doxorubicin—bone cancer	0.00023	0.00248	CcSEcCtD
Atomoxetine—Palpitations—Epirubicin—bone cancer	0.000228	0.00246	CcSEcCtD
Atomoxetine—Loss of consciousness—Epirubicin—bone cancer	0.000227	0.00245	CcSEcCtD
Atomoxetine—Cough—Epirubicin—bone cancer	0.000225	0.00243	CcSEcCtD
Atomoxetine—Vision blurred—Doxorubicin—bone cancer	0.000225	0.00243	CcSEcCtD
Atomoxetine—Convulsion—Epirubicin—bone cancer	0.000224	0.00241	CcSEcCtD
Atomoxetine—Infection—Methotrexate—bone cancer	0.000224	0.00241	CcSEcCtD
Atomoxetine—Nervous system disorder—Methotrexate—bone cancer	0.000221	0.00238	CcSEcCtD
Atomoxetine—Chest pain—Epirubicin—bone cancer	0.00022	0.00237	CcSEcCtD
Atomoxetine—Myalgia—Epirubicin—bone cancer	0.00022	0.00237	CcSEcCtD
Atomoxetine—Arthralgia—Epirubicin—bone cancer	0.00022	0.00237	CcSEcCtD
Atomoxetine—Agitation—Doxorubicin—bone cancer	0.00022	0.00237	CcSEcCtD
Atomoxetine—Anxiety—Epirubicin—bone cancer	0.000219	0.00236	CcSEcCtD
Atomoxetine—Skin disorder—Methotrexate—bone cancer	0.000219	0.00236	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000218	0.00235	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methotrexate—bone cancer	0.000218	0.00235	CcSEcCtD
Atomoxetine—Dry mouth—Epirubicin—bone cancer	0.000215	0.00232	CcSEcCtD
Atomoxetine—Vertigo—Doxorubicin—bone cancer	0.000215	0.00231	CcSEcCtD
Atomoxetine—Anorexia—Methotrexate—bone cancer	0.000215	0.00231	CcSEcCtD
Atomoxetine—Syncope—Doxorubicin—bone cancer	0.000214	0.00231	CcSEcCtD
Atomoxetine—Palpitations—Doxorubicin—bone cancer	0.000211	0.00228	CcSEcCtD
Atomoxetine—Loss of consciousness—Doxorubicin—bone cancer	0.00021	0.00226	CcSEcCtD
Atomoxetine—Infection—Epirubicin—bone cancer	0.000209	0.00226	CcSEcCtD
Atomoxetine—Cough—Doxorubicin—bone cancer	0.000209	0.00225	CcSEcCtD
Atomoxetine—Shock—Epirubicin—bone cancer	0.000207	0.00224	CcSEcCtD
Atomoxetine—Convulsion—Doxorubicin—bone cancer	0.000207	0.00223	CcSEcCtD
Atomoxetine—Nervous system disorder—Epirubicin—bone cancer	0.000207	0.00223	CcSEcCtD
Atomoxetine—Tachycardia—Epirubicin—bone cancer	0.000206	0.00222	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000205	0.00221	CcSEcCtD
Atomoxetine—Skin disorder—Epirubicin—bone cancer	0.000205	0.00221	CcSEcCtD
Atomoxetine—Hyperhidrosis—Epirubicin—bone cancer	0.000204	0.0022	CcSEcCtD
Atomoxetine—Insomnia—Methotrexate—bone cancer	0.000204	0.0022	CcSEcCtD
Atomoxetine—Arthralgia—Doxorubicin—bone cancer	0.000204	0.00219	CcSEcCtD
Atomoxetine—Chest pain—Doxorubicin—bone cancer	0.000204	0.00219	CcSEcCtD
Atomoxetine—Myalgia—Doxorubicin—bone cancer	0.000204	0.00219	CcSEcCtD
Atomoxetine—Anxiety—Doxorubicin—bone cancer	0.000203	0.00219	CcSEcCtD
Atomoxetine—Paraesthesia—Methotrexate—bone cancer	0.000202	0.00218	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000202	0.00218	CcSEcCtD
Atomoxetine—Anorexia—Epirubicin—bone cancer	0.000201	0.00217	CcSEcCtD
Atomoxetine—Somnolence—Methotrexate—bone cancer	0.0002	0.00216	CcSEcCtD
Atomoxetine—Dry mouth—Doxorubicin—bone cancer	0.000199	0.00215	CcSEcCtD
Atomoxetine—Dyspepsia—Methotrexate—bone cancer	0.000198	0.00214	CcSEcCtD
Atomoxetine—Decreased appetite—Methotrexate—bone cancer	0.000196	0.00211	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000195	0.0021	CcSEcCtD
Atomoxetine—Fatigue—Methotrexate—bone cancer	0.000194	0.00209	CcSEcCtD
Atomoxetine—Infection—Doxorubicin—bone cancer	0.000194	0.00209	CcSEcCtD
Atomoxetine—Pain—Methotrexate—bone cancer	0.000193	0.00208	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000192	0.00207	CcSEcCtD
Atomoxetine—Shock—Doxorubicin—bone cancer	0.000192	0.00207	CcSEcCtD
Atomoxetine—Nervous system disorder—Doxorubicin—bone cancer	0.000191	0.00206	CcSEcCtD
Atomoxetine—Insomnia—Epirubicin—bone cancer	0.000191	0.00206	CcSEcCtD
Atomoxetine—Tachycardia—Doxorubicin—bone cancer	0.00019	0.00205	CcSEcCtD
Atomoxetine—Skin disorder—Doxorubicin—bone cancer	0.00019	0.00204	CcSEcCtD
Atomoxetine—Paraesthesia—Epirubicin—bone cancer	0.000189	0.00204	CcSEcCtD
Atomoxetine—Hyperhidrosis—Doxorubicin—bone cancer	0.000189	0.00203	CcSEcCtD
Atomoxetine—Somnolence—Epirubicin—bone cancer	0.000187	0.00202	CcSEcCtD
Atomoxetine—Anorexia—Doxorubicin—bone cancer	0.000186	0.002	CcSEcCtD
Atomoxetine—Feeling abnormal—Methotrexate—bone cancer	0.000186	0.002	CcSEcCtD
Atomoxetine—Dyspepsia—Epirubicin—bone cancer	0.000186	0.002	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methotrexate—bone cancer	0.000184	0.00199	CcSEcCtD
Atomoxetine—Decreased appetite—Epirubicin—bone cancer	0.000183	0.00198	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000182	0.00196	CcSEcCtD
Atomoxetine—Fatigue—Epirubicin—bone cancer	0.000182	0.00196	CcSEcCtD
Atomoxetine—Pain—Epirubicin—bone cancer	0.00018	0.00194	CcSEcCtD
Atomoxetine—Constipation—Epirubicin—bone cancer	0.00018	0.00194	CcSEcCtD
Atomoxetine—Urticaria—Methotrexate—bone cancer	0.000179	0.00193	CcSEcCtD
Atomoxetine—Abdominal pain—Methotrexate—bone cancer	0.000178	0.00192	CcSEcCtD
Atomoxetine—Body temperature increased—Methotrexate—bone cancer	0.000178	0.00192	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000178	0.00192	CcSEcCtD
Atomoxetine—Insomnia—Doxorubicin—bone cancer	0.000176	0.0019	CcSEcCtD
Atomoxetine—Paraesthesia—Doxorubicin—bone cancer	0.000175	0.00189	CcSEcCtD
Atomoxetine—Feeling abnormal—Epirubicin—bone cancer	0.000174	0.00187	CcSEcCtD
Atomoxetine—Somnolence—Doxorubicin—bone cancer	0.000173	0.00187	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Epirubicin—bone cancer	0.000172	0.00186	CcSEcCtD
Atomoxetine—Dyspepsia—Doxorubicin—bone cancer	0.000172	0.00185	CcSEcCtD
Atomoxetine—Decreased appetite—Doxorubicin—bone cancer	0.00017	0.00183	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000168	0.00182	CcSEcCtD
Atomoxetine—Fatigue—Doxorubicin—bone cancer	0.000168	0.00181	CcSEcCtD
Atomoxetine—Urticaria—Epirubicin—bone cancer	0.000168	0.00181	CcSEcCtD
Atomoxetine—Pain—Doxorubicin—bone cancer	0.000167	0.0018	CcSEcCtD
Atomoxetine—Constipation—Doxorubicin—bone cancer	0.000167	0.0018	CcSEcCtD
Atomoxetine—Abdominal pain—Epirubicin—bone cancer	0.000167	0.0018	CcSEcCtD
Atomoxetine—Body temperature increased—Epirubicin—bone cancer	0.000167	0.0018	CcSEcCtD
Atomoxetine—Asthenia—Methotrexate—bone cancer	0.000162	0.00174	CcSEcCtD
Atomoxetine—Feeling abnormal—Doxorubicin—bone cancer	0.000161	0.00173	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Doxorubicin—bone cancer	0.00016	0.00172	CcSEcCtD
Atomoxetine—Pruritus—Methotrexate—bone cancer	0.000159	0.00172	CcSEcCtD
Atomoxetine—Urticaria—Doxorubicin—bone cancer	0.000155	0.00167	CcSEcCtD
Atomoxetine—Body temperature increased—Doxorubicin—bone cancer	0.000154	0.00166	CcSEcCtD
Atomoxetine—Abdominal pain—Doxorubicin—bone cancer	0.000154	0.00166	CcSEcCtD
Atomoxetine—Diarrhoea—Methotrexate—bone cancer	0.000154	0.00166	CcSEcCtD
Atomoxetine—Asthenia—Epirubicin—bone cancer	0.000151	0.00163	CcSEcCtD
Atomoxetine—Pruritus—Epirubicin—bone cancer	0.000149	0.00161	CcSEcCtD
Atomoxetine—Dizziness—Methotrexate—bone cancer	0.000149	0.00161	CcSEcCtD
Atomoxetine—Diarrhoea—Epirubicin—bone cancer	0.000144	0.00155	CcSEcCtD
Atomoxetine—Vomiting—Methotrexate—bone cancer	0.000143	0.00154	CcSEcCtD
Atomoxetine—Rash—Methotrexate—bone cancer	0.000142	0.00153	CcSEcCtD
Atomoxetine—Dermatitis—Methotrexate—bone cancer	0.000142	0.00153	CcSEcCtD
Atomoxetine—Headache—Methotrexate—bone cancer	0.000141	0.00152	CcSEcCtD
Atomoxetine—Asthenia—Doxorubicin—bone cancer	0.00014	0.00151	CcSEcCtD
Atomoxetine—Dizziness—Epirubicin—bone cancer	0.000139	0.0015	CcSEcCtD
Atomoxetine—Pruritus—Doxorubicin—bone cancer	0.000138	0.00149	CcSEcCtD
Atomoxetine—Vomiting—Epirubicin—bone cancer	0.000134	0.00144	CcSEcCtD
Atomoxetine—Nausea—Methotrexate—bone cancer	0.000134	0.00144	CcSEcCtD
Atomoxetine—Diarrhoea—Doxorubicin—bone cancer	0.000133	0.00144	CcSEcCtD
Atomoxetine—Rash—Epirubicin—bone cancer	0.000133	0.00143	CcSEcCtD
Atomoxetine—Dermatitis—Epirubicin—bone cancer	0.000133	0.00143	CcSEcCtD
Atomoxetine—Headache—Epirubicin—bone cancer	0.000132	0.00142	CcSEcCtD
Atomoxetine—Dizziness—Doxorubicin—bone cancer	0.000129	0.00139	CcSEcCtD
Atomoxetine—Nausea—Epirubicin—bone cancer	0.000125	0.00135	CcSEcCtD
Atomoxetine—Vomiting—Doxorubicin—bone cancer	0.000124	0.00134	CcSEcCtD
Atomoxetine—Rash—Doxorubicin—bone cancer	0.000123	0.00133	CcSEcCtD
Atomoxetine—Dermatitis—Doxorubicin—bone cancer	0.000123	0.00132	CcSEcCtD
Atomoxetine—Headache—Doxorubicin—bone cancer	0.000122	0.00132	CcSEcCtD
Atomoxetine—Nausea—Doxorubicin—bone cancer	0.000116	0.00125	CcSEcCtD
Atomoxetine—NPY1R—Signaling by GPCR—GRM1—bone cancer	0.000109	0.00657	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000103	0.00616	CbGpPWpGaD
Atomoxetine—SLC6A4—NRF2 pathway—GSTP1—bone cancer	0.000101	0.00606	CbGpPWpGaD
Atomoxetine—SLC6A4—NRF2 pathway—TGFBR2—bone cancer	0.000101	0.00606	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—GNA11—bone cancer	0.000101	0.00605	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—EZH2—bone cancer	0.0001	0.00602	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—GRM1—bone cancer	9.97e-05	0.00598	CbGpPWpGaD
Atomoxetine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	9.32e-05	0.0056	CbGpPWpGaD
Atomoxetine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	9.2e-05	0.00552	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—GRM4—bone cancer	9.07e-05	0.00544	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—GRM4—bone cancer	9e-05	0.0054	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	8.92e-05	0.00535	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—GRM4—bone cancer	8.81e-05	0.00529	CbGpPWpGaD
Atomoxetine—SLC6A2—NRF2 pathway—GSTP1—bone cancer	8.68e-05	0.00521	CbGpPWpGaD
Atomoxetine—SLC6A2—NRF2 pathway—TGFBR2—bone cancer	8.68e-05	0.00521	CbGpPWpGaD
Atomoxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	8.57e-05	0.00515	CbGpPWpGaD
Atomoxetine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	8.46e-05	0.00508	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—GRM1—bone cancer	7.86e-05	0.00472	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—GRM1—bone cancer	7.8e-05	0.00468	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—GNA11—bone cancer	7.76e-05	0.00466	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—SMO—bone cancer	7.71e-05	0.00463	CbGpPWpGaD
Atomoxetine—SLC6A3—NRF2 pathway—GSTP1—bone cancer	7.69e-05	0.00461	CbGpPWpGaD
Atomoxetine—SLC6A3—NRF2 pathway—TGFBR2—bone cancer	7.69e-05	0.00461	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—GRM1—bone cancer	7.64e-05	0.00459	CbGpPWpGaD
Atomoxetine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	7.56e-05	0.00454	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—GRM4—bone cancer	7.45e-05	0.00447	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—RGS1—bone cancer	7.45e-05	0.00447	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—GNA11—bone cancer	7.4e-05	0.00444	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—GNA11—bone cancer	7.05e-05	0.00423	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—IL3—bone cancer	7.04e-05	0.00422	CbGpPWpGaD
Atomoxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.95e-05	0.00417	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.82e-05	0.00409	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—GRM4—bone cancer	6.68e-05	0.00401	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	6.62e-05	0.00397	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—GRM1—bone cancer	6.46e-05	0.00388	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—GNA11—bone cancer	6.43e-05	0.00386	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL3—bone cancer	6.39e-05	0.00384	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.04e-05	0.00363	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.89e-05	0.00353	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—GRM4—bone cancer	5.8e-05	0.00348	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—GRM1—bone cancer	5.79e-05	0.00348	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	5.75e-05	0.00345	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—CDK4—bone cancer	5.66e-05	0.0034	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—SMO—bone cancer	5.54e-05	0.00333	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—SMO—bone cancer	5.5e-05	0.0033	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—SMO—bone cancer	5.38e-05	0.00323	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.22e-05	0.00313	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—GRM4—bone cancer	5.13e-05	0.00308	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—RGS1—bone cancer	5.13e-05	0.00308	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—GRM4—bone cancer	5.09e-05	0.00305	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—RGS1—bone cancer	5.09e-05	0.00305	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—GRM1—bone cancer	5.03e-05	0.00302	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—GRM4—bone cancer	4.98e-05	0.00299	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—RGS1—bone cancer	4.98e-05	0.00299	CbGpPWpGaD
Atomoxetine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	4.78e-05	0.00287	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—GRM4—bone cancer	4.65e-05	0.00279	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—RGS1—bone cancer	4.65e-05	0.00279	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—RGS1—bone cancer	4.62e-05	0.00277	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—GRM4—bone cancer	4.62e-05	0.00277	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SMO—bone cancer	4.55e-05	0.00273	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—GRM4—bone cancer	4.52e-05	0.00271	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—RGS1—bone cancer	4.52e-05	0.00271	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—JUN—bone cancer	4.47e-05	0.00268	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—GRM1—bone cancer	4.44e-05	0.00267	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—GRM1—bone cancer	4.41e-05	0.00265	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—GRM1—bone cancer	4.32e-05	0.00259	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—GNA11—bone cancer	4.16e-05	0.0025	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—SMO—bone cancer	4.08e-05	0.00245	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—GRM1—bone cancer	4.04e-05	0.00242	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	4.01e-05	0.00241	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—GRM1—bone cancer	4e-05	0.0024	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	3.96e-05	0.00238	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—GRM1—bone cancer	3.92e-05	0.00235	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—ATF1—bone cancer	3.87e-05	0.00232	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—BRAF—bone cancer	3.83e-05	0.0023	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL3—bone cancer	3.78e-05	0.00227	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—GRM4—bone cancer	3.77e-05	0.00227	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—RGS1—bone cancer	3.77e-05	0.00227	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	3.69e-05	0.00222	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—JUN—bone cancer	3.65e-05	0.00219	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	3.64e-05	0.00219	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—SMO—bone cancer	3.54e-05	0.00213	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—GSTP1—bone cancer	3.43e-05	0.00206	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—GRM4—bone cancer	3.43e-05	0.00206	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—RGS1—bone cancer	3.43e-05	0.00206	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	3.39e-05	0.00203	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—GRM4—bone cancer	3.28e-05	0.00197	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—RGS1—bone cancer	3.28e-05	0.00197	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—GRM1—bone cancer	3.27e-05	0.00196	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TGFBR2—bone cancer	3.23e-05	0.00194	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—MDM2—bone cancer	3.21e-05	0.00193	CbGpPWpGaD
Atomoxetine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.19e-05	0.00191	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—GSTP1—bone cancer	3.16e-05	0.0019	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	3.11e-05	0.00187	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IGF1R—bone cancer	3.04e-05	0.00182	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GRM4—bone cancer	2.98e-05	0.00179	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—RGS1—bone cancer	2.98e-05	0.00179	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—GRM1—bone cancer	2.97e-05	0.00178	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—BRAF—bone cancer	2.94e-05	0.00176	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—GNA11—bone cancer	2.86e-05	0.00172	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—SMO—bone cancer	2.84e-05	0.00171	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—GNA11—bone cancer	2.84e-05	0.00171	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—GRM1—bone cancer	2.84e-05	0.00171	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—SMO—bone cancer	2.82e-05	0.00169	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—GNA11—bone cancer	2.78e-05	0.00167	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—SMO—bone cancer	2.76e-05	0.00166	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GRM4—bone cancer	2.75e-05	0.00165	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RGS1—bone cancer	2.75e-05	0.00165	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GRM4—bone cancer	2.73e-05	0.00164	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RGS1—bone cancer	2.73e-05	0.00164	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—JUN—bone cancer	2.69e-05	0.00161	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RGS1—bone cancer	2.67e-05	0.0016	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GRM4—bone cancer	2.67e-05	0.0016	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—GNA11—bone cancer	2.6e-05	0.00156	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—IL3—bone cancer	2.6e-05	0.00156	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GRM1—bone cancer	2.58e-05	0.00155	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—GNA11—bone cancer	2.58e-05	0.00155	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—IL3—bone cancer	2.58e-05	0.00155	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—GNA11—bone cancer	2.53e-05	0.00152	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—IL3—bone cancer	2.52e-05	0.00151	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—MDM2—bone cancer	2.46e-05	0.00148	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—bone cancer	2.41e-05	0.00145	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NDUFA12—bone cancer	2.41e-05	0.00144	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GRM1—bone cancer	2.38e-05	0.00143	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GRM1—bone cancer	2.37e-05	0.00142	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL3—bone cancer	2.36e-05	0.00142	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL3—bone cancer	2.34e-05	0.0014	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GRM1—bone cancer	2.32e-05	0.00139	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL3—bone cancer	2.29e-05	0.00138	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NDUFA12—bone cancer	2.21e-05	0.00133	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—KIT—bone cancer	2.2e-05	0.00132	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—GNA11—bone cancer	2.11e-05	0.00127	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—SMO—bone cancer	2.09e-05	0.00126	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—BRAF—bone cancer	2.07e-05	0.00124	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.06e-05	0.00124	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.04e-05	0.00122	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GRM4—bone cancer	2.02e-05	0.00122	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RGS1—bone cancer	2.02e-05	0.00122	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—EGFR—bone cancer	2.01e-05	0.0012	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NT5C3A—bone cancer	1.99e-05	0.0012	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—GNA11—bone cancer	1.91e-05	0.00115	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL3—bone cancer	1.91e-05	0.00115	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	1.88e-05	0.00113	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NT5C3A—bone cancer	1.83e-05	0.0011	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—GNA11—bone cancer	1.83e-05	0.0011	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—SMO—bone cancer	1.82e-05	0.00109	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GRM4—bone cancer	1.76e-05	0.00106	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RGS1—bone cancer	1.76e-05	0.00106	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GRM1—bone cancer	1.76e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL3—bone cancer	1.74e-05	0.00104	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MDM2—bone cancer	1.74e-05	0.00104	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SMO—bone cancer	1.68e-05	0.00101	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SMO—bone cancer	1.67e-05	0.001	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GNA11—bone cancer	1.66e-05	0.000998	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL3—bone cancer	1.66e-05	0.000996	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	1.64e-05	0.000982	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SMO—bone cancer	1.63e-05	0.00098	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GNA11—bone cancer	1.54e-05	0.000922	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GRM1—bone cancer	1.52e-05	0.000915	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GNA11—bone cancer	1.52e-05	0.000915	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—JUN—bone cancer	1.51e-05	0.000905	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL3—bone cancer	1.51e-05	0.000905	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GNA11—bone cancer	1.49e-05	0.000896	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MMP9—bone cancer	1.47e-05	0.000881	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NDUFA12—bone cancer	1.45e-05	0.000868	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ATF1—bone cancer	1.43e-05	0.000857	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ATF1—bone cancer	1.42e-05	0.000851	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL3—bone cancer	1.39e-05	0.000836	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ATF1—bone cancer	1.39e-05	0.000833	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL3—bone cancer	1.38e-05	0.00083	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL3—bone cancer	1.35e-05	0.000812	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SMO—bone cancer	1.24e-05	0.000742	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NT5C3A—bone cancer	1.2e-05	0.00072	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFBR2—bone cancer	1.19e-05	0.000715	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EGFR—bone cancer	1.19e-05	0.000712	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFBR2—bone cancer	1.18e-05	0.000709	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFBR2—bone cancer	1.16e-05	0.000695	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GNA11—bone cancer	1.13e-05	0.000679	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF1R—bone cancer	1.12e-05	0.000673	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1R—bone cancer	1.11e-05	0.000668	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1R—bone cancer	1.09e-05	0.000654	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SMO—bone cancer	1.07e-05	0.000645	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ATF1—bone cancer	1.05e-05	0.000631	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL3—bone cancer	1.03e-05	0.000616	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—bone cancer	9.96e-06	0.000598	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GNA11—bone cancer	9.82e-06	0.00059	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ATF1—bone cancer	9.13e-06	0.000548	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL3—bone cancer	8.91e-06	0.000535	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFBR2—bone cancer	8.77e-06	0.000526	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ENO2—bone cancer	8.73e-06	0.000524	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1R—bone cancer	8.25e-06	0.000495	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KIT—bone cancer	8.13e-06	0.000488	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—DHFR—bone cancer	8.1e-06	0.000486	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KIT—bone cancer	8.07e-06	0.000484	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ENO2—bone cancer	8.03e-06	0.000482	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KIT—bone cancer	7.9e-06	0.000474	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—BRAF—bone cancer	7.64e-06	0.000459	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFBR2—bone cancer	7.62e-06	0.000457	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—BRAF—bone cancer	7.58e-06	0.000455	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GNA11—bone cancer	7.57e-06	0.000455	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—DHFR—bone cancer	7.45e-06	0.000447	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—BRAF—bone cancer	7.42e-06	0.000446	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—bone cancer	7.4e-06	0.000444	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—bone cancer	7.35e-06	0.000441	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—bone cancer	7.2e-06	0.000432	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1R—bone cancer	7.17e-06	0.00043	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GNA11—bone cancer	6.96e-06	0.000418	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP3A4—bone cancer	6.86e-06	0.000412	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.83e-06	0.00041	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MDM2—bone cancer	6.4e-06	0.000384	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MDM2—bone cancer	6.35e-06	0.000381	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP3A4—bone cancer	6.31e-06	0.000379	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MDM2—bone cancer	6.22e-06	0.000373	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KIT—bone cancer	5.99e-06	0.000359	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—bone cancer	5.87e-06	0.000352	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BRAF—bone cancer	5.63e-06	0.000338	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—JUN—bone cancer	5.56e-06	0.000334	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—JUN—bone cancer	5.52e-06	0.000331	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—bone cancer	5.45e-06	0.000327	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—bone cancer	5.41e-06	0.000325	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—JUN—bone cancer	5.41e-06	0.000324	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—bone cancer	5.4e-06	0.000324	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—bone cancer	5.37e-06	0.000322	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—bone cancer	5.26e-06	0.000316	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ENO2—bone cancer	5.25e-06	0.000315	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KIT—bone cancer	5.2e-06	0.000312	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BRAF—bone cancer	4.89e-06	0.000293	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—DHFR—bone cancer	4.87e-06	0.000292	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—bone cancer	4.74e-06	0.000284	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MDM2—bone cancer	4.71e-06	0.000283	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GNA11—bone cancer	4.55e-06	0.000273	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—bone cancer	4.37e-06	0.000263	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—bone cancer	4.34e-06	0.000261	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—bone cancer	4.25e-06	0.000255	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JUN—bone cancer	4.1e-06	0.000246	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MDM2—bone cancer	4.09e-06	0.000246	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—bone cancer	3.99e-06	0.000239	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—bone cancer	3.67e-06	0.00022	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—bone cancer	3.64e-06	0.000219	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—bone cancer	3.57e-06	0.000214	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JUN—bone cancer	3.56e-06	0.000214	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—bone cancer	3.53e-06	0.000212	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—bone cancer	3.46e-06	0.000208	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—bone cancer	3.22e-06	0.000193	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—bone cancer	3.04e-06	0.000183	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—bone cancer	2.8e-06	0.000168	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—bone cancer	2.8e-06	0.000168	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—bone cancer	2.7e-06	0.000162	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—bone cancer	2.35e-06	0.000141	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—bone cancer	1.83e-06	0.00011	CbGpPWpGaD
